Rubius治疗公司宣布探索战略替代方案和领导层变动的程序

Dannielle Appelhans to Become President and Chief Executive Officer

丹妮尔·阿佩尔汉斯将出任总裁兼首席执行官

Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors

巴勃罗·J·卡诺尼医学博士被任命为董事会主席

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company or a merger. As a result of this process, Rubius is reducing its workforce by 84% and will retain certain employees to execute the process. The Company also announced the appointment of Dannielle Appelhans as president and chief executive officer, effective November 15, 2022. Ms. Appelhans previously served as chief operating officer since joining Rubius in 2021. Current president and chief executive officer, Pablo J. Cagnoni, M.D., was appointed Chair of the Rubius board of directors, effective immediately, and will continue as president and chief executive officer until November 15, 2022.

环球通讯社马萨诸塞州坎布里奇，2022年11月2日-生物制药公司Rubius Treateutics，Inc.(纳斯达克：RUBY)正在开发一种全新的细胞药物，名为红细胞治疗™，用于治疗癌症和自身免疫性疾病，该公司今天宣布，它已经启动了一项程序，探索一系列战略替代方案，以实现股东价值最大化，并计划聘请一家投资银行担任这一过程的战略顾问。将评估的战略选择包括出售全部或部分公司或合并。作为这一过程的结果，Rubius将裁员84%，并将保留某些员工来执行这一过程。本公司还宣布任命丹妮尔·阿佩尔汉斯为总裁兼首席执行官，自2022年11月15日起生效。阿佩尔汉斯自2021年加入Rubius以来一直担任首席运营官。现任总裁兼首席执行官巴勃罗·J·卡格诺尼医学博士被任命为Rubius董事会主席，立即生效，并将继续担任总裁兼首席执行官至2022年11月15日。

Rubius has recently generated new non-human primate data with the next generation cell conjugation RED PLATFORM, demonstrating longer circulation time than observed with the first generation platform and pronounced pharmacodynamic effects as shown by increased levels of interferon gamma, a cytokine critical to both innate and adaptive immunity. In parallel, the Company has advanced a next generation Red Cell Therapeutic, RTX-250, an antigen-specific therapy that is designed to activate dendritic cells.

Rubius最近使用下一代细胞结合红色平台生成了新的非人类灵长类数据，显示出比第一代平台观察到的更长的循环时间，并显示了显著的药效学效应，如干扰素伽马水平的增加，干扰素伽马是一种对先天免疫和获得性免疫都至关重要的细胞因子。与此同时，该公司还推出了新一代红细胞疗法RTX-250，这是一种抗原特异性疗法，旨在激活树突状细胞。

With the first generation Red Cell Therapeutics, Rubius demonstrated that engineered red blood cells could be manufactured at scale, safely administered and activate a patient's immune system, resulting in clinical benefit in certain cancer patients, including evidence of tumor shrinkage and prolonged stable disease in PD-(L)-1 refractory solid tumors.

通过第一代红细胞治疗技术，Rubius证明了可以规模化制造工程红细胞，安全地给药并激活患者的免疫系统，从而为某些癌症患者带来临床益处，包括PD-(L)-1难治性实体肿瘤的肿瘤缩小和长期稳定疾病的证据。

Additional leadership changes include the departures of Pepe Carmona, chief financial officer, and Maiken Keson-Brookes, chief legal officer and corporate secretary. Additional information on the leadership and board changes, and the Company's plan for strategic alternatives, can be found in Rubius' current report on Form 8-K being filed with the U.S. Securities and Exchange Commission on or about the date hereof.

其他领导层变动包括首席财务官佩佩·卡莫纳(Pepe Carmona)和首席法律官兼公司秘书迈肯·凯森-布鲁克斯(Maiken Keson-Brookes)的离职。有关领导层和董事会变动的更多信息，以及该公司的战略选择计划，可以在Rubius目前提交给美国证券交易委员会的8-K表格中找到，表格8-K是在本报告的日期或前后提交的。

About Rubius Therapeutics

关于Rubius Treateutics

Rubius Therapeutics is a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases. Rubius is employing cell conjugation to generate therapeutic red blood cells with two distinct modalities – potent cell-cell interaction and tolerance induction. The Company was named among the 2021 Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit , follow us on Twitter or LinkedIn or like us on Facebook.

Rubius Treateutics是一家生物制药公司，正在开发一种全新的细胞药物，称为红细胞治疗™，用于治疗癌症和自身免疫性疾病。Rubius正在使用细胞结合来产生治疗性红细胞，具有两种不同的方式--有效的细胞-细胞相互作用和耐受诱导。该公司被《波士顿环球报》评为马萨诸塞州2021年最佳工作地点之一，其制造厂最近被普罗维登斯商业新闻评为2022年罗德岛最佳工作地点。欲了解更多信息，请访问，在Twitter或LinkedIn上关注我们，或在Facebook上像我们一样。

Forward-Looking Statements

This press release contains certain statements that constitute "forward-looking statements" within the meaning of applicable laws and regulations and constitute "forward-looking information" within the meaning of applicable securities laws, including, without limitation, statements regarding our plans to initiated a process to explore a range of strategic alternatives and our plans to reduce our operations and execute certain leadership changes.  The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, the possibility that no strategic alternatives or trading market will be available to us and that our stockholders will not realize any value in our shares, as well as those risks identified in our filings with the Commission, including under the heading "Risk Factors" in our Annual Report on Form 10-K for the year-ended December 31, 2021, and subsequent filings with the Commission, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and in our upcoming Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, available on the Commission's website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect our results of operations and cash flows and the amount of time we can meet our operational and capital needs. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Except as required by law, we disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

前瞻性陈述

本新闻稿包含的某些陈述构成了适用法律法规所指的“前瞻性陈述”，并构成了适用证券法所指的“前瞻性信息”，包括但不限于有关我们计划启动一系列战略替代方案的声明，以及我们减少业务和执行某些领导层变动的计划。“可能”、“将”、“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“打算”、“相信”、“估计”、“预测”、“项目”、“潜在”、“继续”、“目标”以及类似的表述旨在识别前瞻性表述，尽管并不是所有前瞻性表述都包含这些识别词语。本新闻稿中的任何前瞻性陈述都是基于管理层目前的预期和信念，受到一些风险、不确定因素和重要因素的影响，这些风险、不确定性和重要因素可能会导致实际事件或结果与本新闻稿中包含的任何前瞻性陈述明示或暗示的内容大不相同，包括但不限于我们将没有战略选择或交易市场可用，我们的股东将无法实现我们股票的任何价值，以及在我们提交给美国证券交易委员会的文件中确定的那些风险。包括在我们截至2021年12月31日的Form 10-K年度报告和随后提交给委员会的文件中，包括我们截至2022年6月30日的Form 10-Q季度报告，以及我们即将发布的截至2022年9月30日的Form 10-Q季度报告, 可在委员会网站www.sec.gov上查阅。任何此类风险和不确定性都可能对我们的运营结果和现金流以及我们满足运营和资本需求的时间产生实质性的不利影响。我们提醒您，不要过度依赖任何前瞻性陈述，这些陈述只反映了它们作出之日的情况。除法律另有要求外，我们没有义务公开更新或修改任何此类陈述，以反映任何此类陈述可能基于的预期或事件、条件或环境的任何变化，或可能影响实际结果与前瞻性陈述中陈述的可能性不同的任何变化。本新闻稿中包含的任何前瞻性陈述仅代表我们截至本新闻稿发布之日的观点，不应被视为代表其在任何后续日期的观点。

We caution that trading in our securities is highly speculative and poses substantial risks. Trading prices for our securities may bear little or no relationship to the actual value realized, if any, by holders of our securities. Accordingly, we urge extreme caution with respect to existing and future investments in our securities.

我们警告，我们的证券交易具有高度的投机性，并构成重大风险。我们证券的交易价格可能与我们证券持有人的实际变现价值几乎或根本没有关系。因此，我们敦促对我们证券的现有和未来投资极其谨慎。

Contact

联系方式

Investors and Media

Lori Murray, Chief Corporate Affairs Officer

lori.murray@rubiustx.com 

投资者和媒体

首席企业事务官Lori Murray

邮箱：lori.Murray@rubiustx.com

炒股开户享福利，入金抽188元红包，100%中奖！

海量资讯、精准解读，尽在新浪财经APP